The Gut-Immune Connection: Probiotics and Respiratory Health

Most of your immune system lives next to your gut. Roughly 70–80% of the body's antibody-producing immune cells sit in tissue along the intestines (called gut-associated lymphoid tissue, or GALT). What happens to the bacteria in your gut shows up in places that don't seem related — including how often you catch a cold. Researchers call this two-way communication the "gut-lung axis," and it is one of the few areas of probiotic research where the trial evidence has held up over time.

What the Trials Show

The flagship study is the Cochrane review by Hao and colleagues. The 2015 update pooled 13 randomized trials with about 3,720 participants and found probiotics reduced the proportion of people who got at least one upper respiratory tract infection (URTI) by roughly half (relative risk about 0.53) and shortened average URTI duration by about 1.9 days. The 2022 Cochrane update by Zhao et al. added more trials and reached a slightly more cautious conclusion: probiotics likely do reduce URTI episodes, with moderate-certainty evidence, though the effect size is smaller than the 2015 review suggested when only the highest-quality trials are included.

Targeted meta-analyses agree that benefit is real but variable: largest in children in daycare, older adults in long-term care, and endurance athletes during heavy training (all groups with elevated respiratory infection rates), and smaller in healthy young adults whose baseline rate of colds is already low.

How It Probably Works

The leading mechanisms are not fully proven but are plausible:

• Mucosal antibodies. Certain probiotic strains increase secretory IgA — the antibody that lines the airways and gut and stops viruses before they can replicate.
• Innate immunity. Some strains boost natural-killer (NK) cell activity in the blood, which helps clear virus-infected cells.
• Calmer inflammation. Probiotic colonization tends to shift gut signaling toward an anti-inflammatory pattern, which can reduce symptom severity even when infection still occurs.

Strain and Dose Matter

"Probiotics" is not a single product. Effects depend on the specific strain, the dose, and whether the bacteria are alive when you swallow them. The most consistent respiratory evidence is for:

• Lactobacillus rhamnosus GG (LGG) — the most-studied strain.
• Multi-strain products combining Lactobacillus and Bifidobacterium species.
• Bifidobacterium animalis subsp. lactis (BB-12).

Generic store-brand "acidophilus" capsules have weaker and less consistent evidence. Look for products that list specific strains (with the strain code, e.g., LGG, BB-12) and a CFU count of at least 1–10 billion per daily dose, plus a "best by" date and storage instructions you can actually follow (refrigeration or shelf-stable).

Reasonable Expectation

Probiotics are not a substitute for vaccines, hand-washing, or masking when you are sick. They are a modest, low-risk add-on most useful for people in higher-exposure settings — daycare-age children, older adults, and athletes in heavy training cycles. For a healthy adult who catches one or two colds a year, the absolute benefit is small, though the safety profile of most well-known strains is excellent.